Use of cytokine therapy in primary immunodeficiency.
Of the six cytokine therapies approved by the US Food and Drug Administration, five of them have been used in patients with primary immunodeficiency (PID). In some applications, clear benefits have been demonstrated, while in others, effects have been more marginal. The most compelling current applications of cytokine therapy in PID are those of granulocyte colony stimulating factor in severe congenital neutropenia and interferon gamma in chronic granulomatous disease. Despite encouraging results with interleukin-2 in common variable immunodeficiency and select other indications, its use in PID is not widespread.
Roy-Ghanta
Sumita
S
Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Sumita.roy-ghanta@uphs.upenn.edu
Orange
Jordan S
JS
D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use; D006105:Granulomatous Disease, Chronic / Q000276:immunology / Q000628:therapy; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy*; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use; D009503:Neutropenia / Q000151:congenital / Q000276:immunology / Q000628:therapy; D016896:Treatment Outcome
D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor; D007371:Interferon-gamma